MediBeacon
MediBeacon’s use of fluorescent tracer agents coupled with transdermal detection technology focuses on providing vital and actionable organ function measurement.
The Transdermal GFR Measurement System Pivotal study (NCT05425719) was completed in 2023. The phase 3 study met pre-negotiated primary and secondary endpoints.
MediBeacon Transdermal measurement of Glomerular Filtration Rate (tGFR) is being shown to have many preclinical nephrology applications with over 500 peer-reviewed publications and conference abstracts in which Transdermal GFR (tGFR) has been used.
